Pembroke & Partners LLC - Apr 8, 2025 Form 4/A - Amendment Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
10%+ Owner
Signature
/s/ Robert J. Eide
Stock symbol
MTNB
Transactions as of
Apr 8, 2025
Transactions value $
$492,000
Form type
4/A - Amendment
Date filed
4/10/2025, 01:54 PM
Date Of Original Report
Feb 25, 2025
Previous filing
Feb 25, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Series C Convertible Preferred Stock Purchase $492K +492 +100% $1,000.00* 984 Apr 8, 2025 Common Stock 840K $0.59 Direct F1, F2, F3
transaction MTNB Warrants Purchase +1.68M +100% 3.36M Apr 8, 2025 Common Stock 1.68M $0.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.
F2 Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power based on the Preferred Stock of up to 23% of the outstanding Common Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.
F3 N/A